AIMS: The aim of this study was to determine whether simvastatin would protect against inflammation-induced aortic stiffening and endothelial dysfunction. METHODS:Aortic pulse wave velocity (aPWV) and flow-mediated dilatation (FMD) were assessed three times, at baseline, after a 14 day administration of simvastatin or placebo and 8 h after Salmonella typhi vaccination in 50 healthy subjects. RESULTS: Following vaccination there was a significant increase in aPWV in the placebo group (5.80 ± 0.87 vs. 6.21 ± 0.97 m s⁻¹, 95% CI 0.19, 0.62, P= 0.002) but not the simvastatin group (5.68 ± 0.73 vs. 5.72 ± 0.74 m s⁻¹, 95% CI -0.19, 0.27, P= 0.9; P= 0.016 for comparison). Whereas FMD response was reduced in the placebo group (6.77 ± 4.10 vs. 5.27 ± 2.88%, 95% CI -2.49, -0.52, P= 0.02) but not in the simvastatin group (7.07 ± 4.37 vs. 7.17 ± 9.94%, 95% CI -1.1, 1.3. P= 0.9, P < 0.001 for comparison). There was no difference in the systemic inflammatory response between groups following vaccination. However, there was a significant reduction in serum apolipoprotein A-I (Apo A-I) in the placebo, but not in the simvastatin, group. CONCLUSIONS:Simvastatin prevents vaccination-induced aortic stiffening and endothelial dysfunction. This protective mechanism may be due to preservation of the Apo A-I lipid fraction, rather than pleiotropic anti-inflammatory effects of statins.
RCT Entities:
AIMS: The aim of this study was to determine whether simvastatin would protect against inflammation-induced aortic stiffening and endothelial dysfunction. METHODS: Aortic pulse wave velocity (aPWV) and flow-mediated dilatation (FMD) were assessed three times, at baseline, after a 14 day administration of simvastatin or placebo and 8 h after Salmonella typhi vaccination in 50 healthy subjects. RESULTS: Following vaccination there was a significant increase in aPWV in the placebo group (5.80 ± 0.87 vs. 6.21 ± 0.97 m s⁻¹, 95% CI 0.19, 0.62, P= 0.002) but not the simvastatin group (5.68 ± 0.73 vs. 5.72 ± 0.74 m s⁻¹, 95% CI -0.19, 0.27, P= 0.9; P= 0.016 for comparison). Whereas FMD response was reduced in the placebo group (6.77 ± 4.10 vs. 5.27 ± 2.88%, 95% CI -2.49, -0.52, P= 0.02) but not in the simvastatin group (7.07 ± 4.37 vs. 7.17 ± 9.94%, 95% CI -1.1, 1.3. P= 0.9, P < 0.001 for comparison). There was no difference in the systemic inflammatory response between groups following vaccination. However, there was a significant reduction in serum apolipoprotein A-I (Apo A-I) in the placebo, but not in the simvastatin, group. CONCLUSIONS:Simvastatin prevents vaccination-induced aortic stiffening and endothelial dysfunction. This protective mechanism may be due to preservation of the Apo A-I lipid fraction, rather than pleiotropic anti-inflammatory effects of statins.
Authors: S Laurent; P Boutouyrie; R Asmar; I Gautier; B Laloux; L Guize; P Ducimetiere; A Benetos Journal: Hypertension Date: 2001-05 Impact factor: 10.190
Authors: Rajesh K Kharbanda; Benjamin Walton; Meredith Allen; Nigel Klein; Aroon D Hingorani; Raymond J MacAllister; Patrick Vallance Journal: Circulation Date: 2002-06-04 Impact factor: 29.690
Authors: Pierre Boutouyrie; Patrick Lacolley; Marie Briet; Véronique Regnault; Alice Stanton; Stéphane Laurent; Azra Mahmud Journal: Drugs Date: 2011-09-10 Impact factor: 9.546
Authors: Sae Young Jae; Eun Sun Yoon; Soo Jin Jung; Sol Gi Jung; Soo Hyun Park; Byung Sung Kim; Kevin S Heffernan; Bo Fernhall Journal: Eur J Appl Physiol Date: 2013-04-25 Impact factor: 3.078
Authors: Kaisa M Mäki-Petäjä; Lisa Day; Joseph Cheriyan; Frances C Hall; Andrew J K Östör; Nicholas Shenker; Ian B Wilkinson Journal: J Am Heart Assoc Date: 2016-02-19 Impact factor: 5.501
Authors: Elizabeth C Lefferts; Brooks A Hibner; Wesley K Lefferts; Natalia S Lima; Tracy Baynard; Jacob M Haus; Abbi D Lane-Cordova; Shane A Phillips; Bo Fernhall Journal: Physiol Rep Date: 2021-11
Authors: Anant R C Patel; Beverly S Kowlessar; Gavin C Donaldson; Alex J Mackay; Richa Singh; Siobhan N George; Davinder S Garcha; Jadwiga A Wedzicha; John R Hurst Journal: Am J Respir Crit Care Med Date: 2013-11-01 Impact factor: 21.405